Knowledge Services

Everything you need to know about Federal policies impacting your work.


Real-time “what-it-means-to-you” analysis of key Federal policies impacting your goals


Forward-looking insight into the policy trajectory for your priority issues


In-depth, actionable breakdowns of all relevant regulations and guidance


Concise summaries of impactful policy-driving events, including congressional hearings, agency forums, and MedPAC and MACPAC sessions


Detailed briefs of major health care bills, with assessments of their probability of passage and tracking of relevant legislation


Monitoring of all relevant Federal grant, advisory board nomination, and demonstration opportunities


Our proprietary Issue Brief series, breaking down the status of the hottest topics in health


A Weekly newsletter framing the upcoming week and recapping recent developments of interest

Policy Hub

Unlimited subscriptions to Policy Hub, our searchable knowledge database and daily e-digest


Commissioners Approve Recommendations to Allow States to Restrict Drug Coverage Based on Medicare Coverage with Evidence Development Decisions

The Medicaid and CHIP Payment and Access Commission (MACPAC) convened a session to review its draft chapter on Medicaid coverage based on Medicare National Coverage Determinations (NCDs) and draft recommendations. Principal Policy Analyst Chris Park presented revised policy options to the Commissioners that would allow Medicaid to restrict coverage of covered outpatient drugs based on Medicare NCD or NCDs with… (Slifer, January 27, 2023) #Coverage Decisions, #Prescription Drugs

Commission Begins Work Examining the Role of External Quality Reviews for Managed Care

The Medicaid and CHIP Payment and Access Commission (MACPAC) convened a session on the role of external quality review (EQR) in managed care oversight and accountability. This builds on the Commission’s work on managed care oversight, including rate setting, risk mitigation, and state procurement practices. Principal Analyst Sean Dunbar detailed that the Commission’s new work on examining states’ EQR approaches… (Slifer, January 27, 2023) #Quality, #Transparency

Temporary Final Guidance Issued to Allow for the Compounding of Ibuprofen Oral Suspension Products to Address Shortages

The Food and Drug Administration (FDA) issued immediately in effect final guidance on compounding certain ibuprofen oral suspension products in outsourcing facilities for administration in hospitals and health systems. The agency details that the FDA has received reports related to increased demand for pediatric fever-reducing medication, including ibuprofen oral suspension products, along with health systems and hospitals experiencing challenges in… (Slifer, January 24, 2023) #Food and Drug Administration, #Hospitals, #Prescription Drugs